Yes, cystic fibrosis (CF) is a genetic disorder. It is the most common autosomal recessive disorder in people of European descent, caused by mutations in a single gene called CFTR. A child must inherit a faulty copy of this gene from both parents to develop the disease.
How the CFTR Gene Works
The CFTR gene provides instructions for building a protein that acts as a channel on the surface of cells, allowing chloride and bicarbonate ions to flow in and out. This movement of salt controls how much water sits on cell surfaces, which keeps the mucus lining your lungs, digestive tract, and other organs thin and slippery.
When the CFTR gene is mutated, the protein either doesn’t reach the cell surface, doesn’t open properly, or isn’t produced at all. Without a working channel, salt and water can’t move normally. The result is thick, sticky mucus that builds up in the lungs, pancreas, liver, and reproductive organs. CFTR also acts as a regulator of other ion channels, so its absence throws off the entire balance of fluid on cell surfaces.
Inheritance Pattern
CF follows an autosomal recessive pattern, meaning the gene sits on a non-sex chromosome and a child needs two broken copies to develop the disease. People who carry just one faulty copy are called carriers. Carriers produce enough working CFTR protein from their one functional gene copy that they don’t have symptoms and typically never know they carry the mutation unless they’re tested.
When both parents are carriers, each pregnancy has a 25% chance of producing a child with CF, a 50% chance of producing a carrier, and a 25% chance of producing a child with two normal copies. These odds reset with every pregnancy. Having one child with CF doesn’t change the probability for the next.
Carrier rates vary by ethnicity. In Europe, roughly 3.3 to 4% of the population carries a CFTR mutation. In the United States, about 3.8% of the overall population are carriers. Rates are much lower in East Asian populations, where carrier frequency in China has been estimated at around 0.5 to 0.6%.
What CF Does to the Body
The lungs take the hardest hit. Thick mucus clogs the airways, trapping bacteria and triggering chronic infections and inflammation. Over time, repeated lung infections cause permanent damage. This is the primary driver of illness and hospitalization for most people with CF.
The same sticky mucus blocks the ducts of the pancreas, preventing digestive enzymes from reaching the small intestine. Without those enzymes, the body struggles to break down fats and absorb nutrients, leading to poor weight gain, greasy stools, and nutritional deficiencies. The bile duct connecting the liver and gallbladder to the intestine can also become blocked and inflamed.
CF affects reproduction as well. Nearly all men with CF are infertile because the vas deferens, the tube connecting the testicles to the prostate gland, is either blocked with mucus or missing entirely. Women with CF can conceive but may face complications related to thicker cervical mucus and overall health.
How CF Is Diagnosed
In the United States, every newborn is screened for CF shortly after birth. The initial test measures a substance called immunoreactive trypsinogen (IRT) in the baby’s blood. IRT is made by the pancreas and tends to be elevated in newborns with CF. If IRT is high, a second test on the same blood sample looks for mutations in the CFTR gene.
A baby with high IRT and two or more CFTR mutations likely has CF, but the diagnosis still needs confirmation. A baby with high IRT and only one mutation may or may not have the disease. In either case, the next step is a sweat test, which measures the concentration of chloride in sweat. A reading of 60 mmol/L or higher confirms a CF diagnosis. Normal is 29 mmol/L or less, while results between 30 and 59 mmol/L fall into an intermediate range that requires further evaluation, often including more comprehensive genetic testing.
Carrier Screening and Family Planning
Carrier screening is a simple blood test that can identify whether you carry a CFTR mutation. The American College of Obstetricians and Gynecologists recommends that carrier screening be offered to anyone who is pregnant or planning a pregnancy. If one partner tests positive, the other should also be tested.
When both partners are carriers, several reproductive options exist. Preimplantation genetic testing can be used during IVF to select embryos that don’t have two faulty copies of the gene. Prenatal diagnostic testing, including chorionic villus sampling as early as 10 weeks or amniocentesis between 15 and 20 weeks, can determine whether a fetus has CF or is a carrier. These results give families time to prepare, seek specialist care, or make informed decisions about the pregnancy.
Treatments That Target the Genetic Defect
For decades, CF treatment focused on managing symptoms: clearing mucus from the lungs, replacing pancreatic enzymes, and fighting infections with antibiotics. That changed with the development of CFTR modulators, drugs designed to fix the malfunctioning protein itself rather than just treating its downstream effects.
There are currently five approved CFTR modulators. The most widely used is Trikafta, approved for people ages 2 and older who carry at least one copy of the F508del mutation, which is the most common CF-causing mutation. A newer option called Alyftrek was approved for people ages 6 and older who are eligible for Trikafta or who have one of 31 specified rare mutations. Other modulators, including Symdeko, Orkambi, and Kalydeco, cover different mutation types and age groups. Kalydeco, the first modulator approved, works specifically on gating mutations where the protein reaches the cell surface but the channel doesn’t open properly. It essentially holds the gate open so chloride can flow through.
These drugs have transformed outcomes. The Cystic Fibrosis Foundation reports that the median predicted survival for people with CF born between 2020 and 2024 is now 65 years, a dramatic improvement from previous decades when many patients did not survive past their 30s. Not everyone with CF has a mutation that responds to current modulators, but for those who do, lung function, nutritional status, and quality of life have improved substantially.